Enterovirus D68: a test case for the use of immunological surveillance to develop tools to mitigate the pandemic potential of emerging pathogens
- PMID: 35036969
- PMCID: PMC8741221
- DOI: 10.1016/S2666-5247(21)00312-8
Enterovirus D68: a test case for the use of immunological surveillance to develop tools to mitigate the pandemic potential of emerging pathogens
Conflict of interest statement
SRD reports contracts from Biofire Diagnostics and Pfizer; consulting fees from Biofire Diagnostics, DiaSorin Molecular, and Karius, outside the submitted work. MRV reports grants from the US National Institute of Allergy and Infectious Disease, the Thrasher Research Fund, the Pediatric Infectious Diseases Society Foundation; consulting fees from IDBiologics and HDT Bio, outside the submitted work. MRV is also an inventor a pending international patent application on human monoclonal antibodies to enterovirus D68. SP reports contracts from Merck Vaccines and Moderna for institutional sponsored programmes, and consulting fees from Moderna, Merck, Dynavax, Pfizer, and HOOKIPA Biotech, outside the submitted work. All other authors declare no competing interests. HN-T and SWP contributed equally.
References
-
- Park SW, Pons-Salort M, Messacar K, et al. Epidemiological dynamics of enterovirus D68 in the United States and implications for acute flaccid myelitis. Sci Transl Med. 2021;13 - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources